Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Stock Performance

NASDAQ:EVGN opened at $2.40 on Thursday. Evogene has a 52 week low of $2.14 and a 52 week high of $10.40. The firm has a market cap of $98.92 million, a price-to-earnings ratio of -5.22 and a beta of 1.40. The firm’s 50-day simple moving average is $3.09 and its 200 day simple moving average is $5.28.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The business had revenue of $0.91 million for the quarter.

Hedge Funds Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets lifted its stake in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.